MAY 23, 2020 10:21 AM PDT

Can metformin treat lymphoma?

A popular diabetes medication may be useful in treating cancer, according to new research published recently in Cell Reports Medicine. The medication, biguanides, is most commonly known as metformin and is used to control blood sugar for people with Type 2 diabetes. The medication’s ability to target cell metabolism has interested cancer researchers for some time; this research adds to that interest by identifying a biomarker that could detect which cancers would respond to biguanides.

"Cancers vary widely in how they react to different therapies -- what works for one cancer type may not work for another -- but regardless, they are all reliant on metabolism for energy production," said senior author of the study and Van Andel Institute Professor Russell Jones, Ph.D. Dr. Jones is also the leader of VAI's Metabolic and Nutritional Programming group. 

Past attempts to use biguanides to treat cancer have been limited because of two main reasons: 1) it is difficult to predict which cancers will respond to treatment and 2) it is challenging to deliver enough of the drug into cancer cells so that it is effective. This study addresses the first concern.

"Our results establish two important things: First, they give us a way to objectively determine which types of cancer are sensitive to biguanide treatment and, second, they illuminate how and why some patients may respond better to biguanides than other patients," explains Dr. Jones. 

In the study, the research team found a microRNA regulated by the gene MYC that is a biomarker for cancers that respond to biguanide. MYC is a gene that is related to metabolic activity in cancer cells and that is present in many lymphomas. Watch the video below to learn more about the MYC gene.

This finding has significant implications, say the researchers. "Biguanides have great potential as cancer treatments, particularly for blood cancers," comments Dr. Jones. "Biomarkers such as what we have found here are vital tools for determining which cancers will respond to biguanides and which will not, which is important for patient care as well as designing more effective clinical trials."

Sources: Cell Reports Medicine, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 18, 2020
Cancer
Itraconazole: the key is in the dosage
SEP 18, 2020
Itraconazole: the key is in the dosage
Precision medicine specific to a patient’s genetics or immune system is spearheading new paths of cancer treatment ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
OCT 08, 2020
Immunology
Immuno Metabolic Complexity and Modulating Metabolites
OCT 08, 2020
Immuno Metabolic Complexity and Modulating Metabolites
Immunometabolism is a relatively new subspecialty of immunology as we’ve begun to unravel the complex metabolic re ...
OCT 08, 2020
Cancer
Oral cancer pain levels indicate metastasis
OCT 08, 2020
Oral cancer pain levels indicate metastasis
A new study from NYU College of Dentistry researchers provides insight as to why patients with metastatic oral cancer ex ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
Loading Comments...